Asylia Therapeutics Closes $14.5M

Development-stage biotechnology company, Asylia Therapeutics has closed $14.5 million in financing. Founded in 2019, the company advances novel immune-modulating therapies for cancer and autoimmune diseases. The series A round, led by Sporos Bioventures LLC, will bring Asylia's assets to first-in human clinical trials for oncology.

Simultaneously, the new capital will potentially generate proof-of-concept signals in autoimmune diseases, like lupus. Asylia Therapeutics shares many commonalities with its lead investor, Houston-based, Sporos Bioventures. Highly dedicated to targeting diseases linked to cancer and immune system dysfunction, Sporos also upholds a patient-first approach, prioritizing readily-available and cost-effective treatment.

READ MORE: DeepScribe Earns $5.2 Million...

Login In


Register now for free access

Notify of
Inline Feedbacks
View all comments